EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

A pilot point-of-care kidney disease clinic in primary care to pharmacologically optimise people with chronic kidney disease (PROTECT KIDNEY)

Rouvick Mariano Gama iD, Kathryn Griffiths, Nathan Beencke, Kathryn Dalrymple, Stephanie Mitchell, Prema Ravi, Joseph Mayhew, Sharlene Greenwood iD, Kate Bramham

Family Practice · 2025

DOI: 10.1093/fampra/cmaf083 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Family Practice, 2025. Verfasst von Rouvick Mariano Gama und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Inflammation Biology, Faculty of Life Sciences and Medicine, King's College London, London SE5 9NU, United Kingdom. Hauptthemen laut MEDLINE: Primary Health Care, Renal Insufficiency, Chronic, Point-of-Care Testing, Proteinuria. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kidney Research United Kingdom.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic kidney disease (CKD) is increasing in prevalence and is associated with substantial morbidity and mortality. Early initiation of cardiorenal protective medications is recommended to improve outcomes. Barriers to implementation include renal function monitoring and resources to initiate and titrate treatment. We aimed to evaluate the feasibility and acceptability of a protocolled point-of-care testing (POCT) pathway to optimise people living with proteinuric CKD in primary care.

Method

A pilot quality improvement study conducted across three general practices in Greater London, United Kingdom. Inclusion criteria were adults (18–80 years) with hypertension and/or type 2 diabetes mellitus, proteinuria, and reduced kidney function (eGFR 30–75 ml/min/1.73m2), who were identified using electronic health records. POCT for creatinine and potassium enabled real-time decision-making using a traffic light clinical decision support system. The primary outcome was recruitment rate and patient acceptability. Secondary efficacy outcomes included medication optimisation and renal function changes.

Results

Twenty-five (52%) of 48 patients agreed to participate. Overall, 23/25 (92%) completed the pathway and 20/25 (80%) achieved pharmacological optimisation. There were no significant adverse events. POCT was successful in 44/57 (77%) of cases and well tolerated by most participants (10/13; 77%). Patient satisfaction was high (12/13; 92%), with most preferring advanced nurse practitioners or pharmacists in future clinics.

Conclusion

A POCT-led CKD optimisation pathway is feasible and well-accepted in primary care. While high medication optimisation rates were achieved, barriers to recruitment and engagement remain. Future studies should evaluate scalability, long-term clinical impact, and cost-effectiveness to inform wider implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary Health CareRenal Insufficiency, ChronicPoint-of-Care TestingProteinuriaDiabetes Mellitus, Type 2Pilot ProjectsQuality ImprovementFeasibility StudiesGeneral PracticeLondonDecision Support Systems, ClinicalPatient Acceptance of Health CareCreatininePotassiumHypertensionGlomerular Filtration RatePatient SatisfactionSodium-Glucose Transporter 2 InhibitorsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsHumansMaleFemaleMiddle AgedAged

Stichwörter der Autor:innen

chronic kidney diseasepoint-of-careprimary caresodium-glucose-cotransporter-2 inhibitors

Substanzen

CreatininePotassiumSodium-Glucose Transporter 2 InhibitorsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor Antagonists

Autor:innen und Institutionen

  • Department of Inflammation Biology, Faculty of Life Sciences and Medicine, King's College London, London SE5 9NU, United Kingdom.
  • King's Kidney Care, King's College Hospital, King's College Hospital NHS Foundation Trust, London SE5 9RS, United Kingdom.
  • Department of Women and Children' Health, Faculty of Life Sciences and Medicine, King's College London, London SE5 9RJ, United Kingdom.
  • Department of Long-Term Conditions, Health Innovation Network South London, London SE1 7EU, United Kingdom.
  • Department of Nutritional Sciences, Faculty of Life Sciences and Medicine, King's College London, London SE1 9NH, United Kingdom.
  • Chelsfield Surgery, Orpington Primary Care Network, Orpington BR6 6HD, United Kingdom.

ORCID-Profile: Rouvick Mariano Gama, Sharlene Greenwood

Förderung

  • Kidney Research United Kingdom

Zitieren

APA

Gama, R. M., Griffiths, K., Beencke, N., Dalrymple, K., Mitchell, S., Ravi, P., Mayhew, J., Greenwood, S., & Bramham, K. (2025). A pilot point-of-care kidney disease clinic in primary care to pharmacologically optimise people with chronic kidney disease (PROTECT KIDNEY). Family Practice. https://doi.org/10.1093/fampra/cmaf083

Vancouver

Gama RM, Griffiths K, Beencke N, Dalrymple K, Mitchell S, Ravi P, et al. A pilot point-of-care kidney disease clinic in primary care to pharmacologically optimise people with chronic kidney disease (PROTECT KIDNEY). Family Practice. 2025. doi:10.1093/fampra/cmaf083

BibTeX
@article{Gama2025,
  author = {Gama, Rouvick Mariano and Griffiths, Kathryn and Beencke, Nathan and Dalrymple, Kathryn and Mitchell, Stephanie and Ravi, Prema and Mayhew, Joseph and Greenwood, Sharlene and Bramham, Kate},
  title = {A pilot point-of-care kidney disease clinic in primary care to pharmacologically optimise people with chronic kidney disease (PROTECT KIDNEY)},
  journal = {Family Practice},
  year = {2025},
  doi = {10.1093/fampra/cmaf083}
}
Kostenlos starten →